01
Apr
2013
First experience with enzyme replacement therapy during pregnancy and lactation in Pompe disease
Experience
Written by Administrator   

An article published on PubMed.gov, Dec. 2011, describes a 40-year old woman with Pompe Disease who successfully carried a healthy baby to term. She continued to receive enzyme replacement therapy (ERT) with alglucosidase alfa. There were no maternal complications and the child developed normally. One year after delivery the mother's physical condition was similar as prior to her pregnancy.

To view the full text, click here.

Source: PubMed.gov

 
19
Mar
2013
Guy Ashford-Smith on Handi-Link, interview by Cam Wells, CJAM radio, 03/19/2013
Interviews
Written by Administrator   

This program focuses on disability issues. Host Cam Wells will explore all sides of this comparing and contrasting with able bodied life.

Handi-Link Interview

 
27
Mar
2013
2013 CAP Meeting - Save the Date!
Events
Written by Brad Crittenden   

The 2013 Canadian Association of Pompe National Meeting will be help in Toronto, June 8-9. Save the date!

 
19
Mar
2013
BioMarin to Advance BMN-701 for Pompe Disease to Next Phase of Development
Press Releases
Written by Biomarin Pharmaceuticals   

SAN RAFAEL, Calif., March 19, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today results from POM-001, the Phase 1/2 trial for BMN-701, a fusion protein of insulin-like growth factor 2 and acid alpha-glucosidase (IGF2-GAA) for the treatment of late-onset Pompe disease. The results exceeded the company's pre-specified requirements for proceeding to the next phase of development...

Source: GlobalNewsWire

 
 

Design by PacificByte